Price
Frequently asked questions
What is Evotec's market capitalization?
What is the Earnings Per Share (EPS) for Evotec?
What are the analyst ratings and target price for Evotec's stock?
What is Evotec's revenue over the trailing twelve months?
What is the free cash flow of Evotec?
How many employees does Evotec have, and what sector and industry does it belong to?
What is the free float of Evotec's shares?
Financials
- Market Cap
- $1.55B
- EPS (TTM)
- -$1.008
- Free Float
- 131.39M
- Revenue (TTM)
- $810.48M
- Free Cashflow (TTM)
- -$213.39M
Pricing
- 1D span
- $8.335$8.795
- 52W span
- $5.53$24.09
Analyst Ratings
The price target is $11.00 and the stock is covered by 11 analysts.
Buy
6
Hold
4
Sell
1
Information
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
- Employees
- 5,000
- Industries
- Pharmaceuticals: Major
- Sector
- Health Care
Identifier
- ISIN
- DE0005664809
- Primary Ticker
- EVT